Business Wire

Regula Software Now Supports the Latest Standard for Biometric Passport Verification

18.2.2025 14:00:00 CET | Business Wire | Press release

Share

With its latest update, Regula Document Reader SDK, a comprehensive software solution for identity document verification, ensures 100% support for the new ISO/IEC 39794-5 standard regulating the methods of facial data storage and verification in e-passport chips. According to the ICAO guidelines, all document readers and verification systems must be compatible with the new standard by 2026, with passport issuers required to fully adopt the new format by 2030.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218969889/en/

Regula Document Reader SDK correctly extracts and verifies facial data encoded in the e-passport chip under the new ISO/IEC 39794-5 standard. (Graphic: Regula)

The ISO/IEC 39794-5 standard introduces an enhanced framework for facial image data, significantly improving interoperability, processing speed, and recognition accuracy across different identity verification (IDV) systems worldwide. Unlike the previous ISO/IEC 19794-5:2005 standard, which primarily stored a basic facial image, the new format records additional metadata, including detailed facial landmarks, precise eye and hair color, and other biometric attributes.

Why this matters

The richer set of pre-stored reference points eliminates the need for separate face detection and feature extraction during verification. Instead of calculating key facial points from scratch, IDV systems can use the pre-recorded metadata, accelerating processing times and ensuring consistent, high-quality recognition results—regardless of the local algorithm used for comparison. This standardization guarantees that a person’s face in their passport will be consistently and accurately verified across different countries, improving global interoperability.

Apart from that, the ISO/IEC 39794-5 standard implements a flexible framework for future extensions. This means that as new attributes or enhancements are introduced in the future, all systems supporting this standard will remain fully functional without requiring urgent updates—unlike the current situation, where all IDV systems would need to be updated to accommodate new data formats.

Preparing for the transition

Although the current ISO/IEC 19794-5:2005 will remain valid, the industry has started the transition period, and businesses worldwide should be ready to process the new format data before 2026.

Regula’s long-standing expertise in secure RFID chip reading and trustworthy data verification ensured smooth adaptation to the new standard even prior to its coming into force. The company’s participation in the recent testing event in Australia demonstrated its ability to correctly extract, interpret, and verify biometric facial data encoded according to ISO/IEC 39794-5. This means that identity verification systems using Regula’s software are future-proofed against compatibility issues that could arise as countries transition to the new format.

In addition, the new standard will require organizations from banks to border control to update their passport readers with software that fits this standard. Regula's IDV software is compatible with most document readers on the market and can be easily used with any device model. This implies a seamless transition to the new standard without replacing existing hardware, ensuring a cost-effective and hassle-free upgrade.

“The shift to ISO/IEC 39794-5 is a major step forward in improving compatibility and efficiency in biometric verification. With more detailed metadata now embedded in e-passports, identity verification systems can achieve faster processing and more accurate recognition results. Our expertise in RFID chip processing ensures that Regula’s technology is already fully equipped to support this transition, providing organizations with seamless, future-proof solutions that help them stay in line with regulatory changes,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To get additional information about the latest update to Regula Document Reader SDK, read the technical documentation. If you are interested in learning more about how Regula processes RFID chip data, visit the official website.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218969889/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye